Results- Financial Results for September 30, 2026.

Ref: Syn/CS/SE/BM/2026-27/Oct/05 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com October 27, 2026 To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Sub: Outcome of the Board Meeting Dear Sir/Madam, Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors, at its meeting held today i.e. October 27, 2026, has inter-alia, considered and approved the Un-audited financial results (standalone and consolidated) as per Indian Accounting Standards (Ind-AS) for the quarter and half year ended September 30, 2026. A copy of the unaudited financial results along with the Limited Review Reports is enclosed herewith. The Board Meeting commenced at 15:15 (IST) and concluded at 18:30 (IST). The above information will also be made available on the website of the Company at www.syngeneintl.com. Kindly take the above information on record. Thanking You Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Chethan Yogesh Company Secretary and Compliance Officer Encl: a/a SYNGENE INTERNATIONAL LIMITED CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026 (Rs. in million, except per share data) Sl. No. Particulars 3 months ended Preceding Corresponding 3 Year to date figures Year to date figures Previous year ended 30 September 2026 3 months ended months ended in the for the current period for the previous period 31 March 2026 30 June 2026 previous year 30 ended ended September 2025 30 September 2026 30 September 2025 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income a) Revenue from operations 8,327 7,360 9,106 1 5,687 1 7,851 37,387 b) Other Income 2 80 253 154 533 331 707 Total Income 8,607 7,613 9,260 1 6,220 18,182 3 8,094 2 Expenses a) Cost of chemicals, reagents and consumables consumed 2,030 1,782 2,275 3,812 4 ,670 9,112 b) Changes in inventories of finished goods and work-in-progress (44) (48) 110 (92) ( 109) 7 4 c) Employee benefits expense 2,727 2,711 2,855 5,438 5 ,567 11,490 d) Finance costs 1 00 9 6 132 196 248 488 e) Depreciation and amortisation expense 1,117 1,122 1,165 2,239 2 ,277 4,529 f) Other expenses 1,526 1,506 1,753 3,032 3 ,498 6,917 g) Foreign exchange fluctuation loss, net 6 14 501 118 1,115 166 609 Total expenses 8,070 7,670 8,408 15,740 1 6,317 3 3,219 3 Profit before tax and exceptional items (1-2) 5 37 ( 57) 8 52 4 80 1 ,865 4 ,875 4 Exceptional Items, net gain/ (loss) [refer note 6 & 7] ( 67) ( 135) - (202) - (766) 5 Profit before tax (3-4) 470 ( 192) 8 52 278 1,865 4,109 6 Tax expense Current tax 9 4 1 177 9 5 405 870 Deferred tax 5 4 (103) 4 (49) ( 78) 7 2 Total tax expense 148 ( 102) 181 46 3 27 942 7 Profit for the period / year (5-6) 322 ( 90) 6 71 232 1,538 3,167 8 Other comprehensive income (A) (i) Items that will not be reclassified to profit or (loss) ( 23) (6) (54) (29) ( 51) (63) (ii) Income tax relating to items that will not be reclassified to profit or (loss) 3 2 1 4 5 13 1 6 (B) (i) Items that will be reclassified to profit or (loss) 1 42 478 ( 1,890) 620 (1,603) ( 2,679) (ii) Income tax relating to items that will be reclassified to profit or (loss) (15) (121) 542 (136) 467 766 Other comprehensive income for the period / year, net of taxes 1 07 3 53 ( 1,388) 4 60 ( 1,174) ( 1,960) 9 Total comprehensive income for the period / year (7+8) 4 29 2 63 ( 717) 6 92 3 64 1 ,207 10 Paid-up equity share capital (Face value of Rs.10 each) [refer note 4] 4,037 4,037 4,029 4,037 4,029 4,029 11 Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity' 44,362 12 Earnings per share (of Rs.10 each) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) a) Basic 0 .80 (0.22) 1.67 0.58 3 .82 7.87 b) Diluted 0 .80 (0.22) 1.67 0.58 3 .82 7.87 See accompanying notes to the financial results SYNGENE INTERNATIONAL LIMITED CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099 CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES (Rs. in Million) As at As at Particulars 30 September 2026 31 March 2026 (Unaudited) (Audited) ASSETS Non-current assets Property, plant and equipment 24,475 25,454 Capital work-in-progress [refer note 5] 11,406 10,404 Right-of-use assets 3,639 3,845 Investment property 210 315 Other intangible assets 431 386 Intangible assets under development 47 53 Financial assets (i) Investments 2,005 2,863 (ii) Derivative assets 248 317 (iii) Other financial assets 1,946 3,116 Deferred tax assets (net) 930 1,007 Income tax assets (net) 1,548 1,088 Other non-current assets 219 133 Total non-current assets 47,104 48,981 Current assets Inventories 1,678 1,413 Financial assets (i) Investments 4,093 4,610 (ii) Trade receivables 3,855 5,088 (iii) Cash and cash equivalents 1,199 2,286 (iv) Bank balances other than (iii) above 8 2,021 (v) Derivative assets 26 69 (vi) Other financial assets 6,765 4,247 Other current assets 1,857 1,687 Total current assets 19,481 21,421 Total assets 66,585 70,402 EQUITY AND LIABILITIES Equity Equity share capital 4 ,037 4,029 Other equity 44,551 44,362 Total equity 48,588 48,391 Liabilities Non-current liabilities Financial liabilities (ii) Lease liabilities 4,193 4,303 (iii) Derivative liabilities 196 488 (iii) Other financial liabilities 2 1 Provisions - 180 Other non-current liabilities 1,777 1,979 Total non-current liabilities 6,168 6,951 Current liabilities Financial liabilities (i) Borrowings 672 94 (ii) Lease liabilities 209 187 (iii) Trade payables total outstanding dues of micro and small enterprises 604 588 total outstanding dues of creditors other than micro and small enterprises 2,429 2,221 (iv) Derivative liabilities 1,043 1,145 (v) Other financial liabilities 1,282 1,775 Provisions 832 1,144 Current tax liabilities (net) 84 98 Other current liabilities 4,674 7,808 Total current liabilities 11,829 15,060 Total equity and liabilities 66,585 70,402 SYNGENE INTERNATIONAL LIMITED CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099 CONSOLIDATED STATEMENT OF CASH FLOWS (Rs. in Million) Six months ended Six months ended Particulars 30 September 2026 30 September 2025 (Unaudited) (Unaudited) 1 Cash flows from operating activities Profit for the year 232 1 ,538 Adjustments to reconcile profit after tax to net cash flows: Depreciation and amortisation expense 2 ,239 2 ,277 (Gain)/loss on disposal of property, plant and equipment (net) ( 25) 11 Impairment allowances of doubtfull trade receivables 47 (11) Bad debts written off - 278 Advances to suppliers written off (7) - Share-based payment expenses (net) 4 216 Interest expense 196 250 Unrealised foreign exchange gain ( 36) (21) Net gain on sale of current investments ( 64) (46) Interest income ( 419) ( 286) Interest on Income tax refund ( 51) - Tax expenses 46 327 Operating profit before working capital changes 2 ,162 4 ,533 Movements in working capital Decrease/ (increase) in inventories ( 265) ( 338) Decrease/ (increase) in trade receivables 1 ,169 ( 351) Decrease/ (increase) in other financial and othe [Showing first 8,000 characters — download PDF for full document]